|drug472||Blood sample Wiki||0.30|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.
Description: Time to treatment failure during the 28-day treatment period. Treatment failure is defined as additional or alternative treatment required, or intubation and invasive ventilation, or transfer to intensive care unit, or death.Measure: Evaluation of EPA-FFA efficacy compared to placebo Time: 28 days
Description: To determine whether EPA-FFA gastro-resistant capsules decreases the time to and amount of clinical improvement as determined by the WHO 9-point ordinal scale during the study.Measure: Time to and amount of clinical improvement Time: 28 days
Description: To determine whether EPA-FFA gastro-resistant capsules increases the number of subjects alive and discharged home without supplemental oxygen therapy.Measure: Change in recovery and survival rate Time: 28 days
Description: To determine whether EPA-FFA gastro-resistant capsules decreases CRP and IL-6 during the study.Measure: Reduction of CRP and IL-6 Time: 28 days
Description: To determine whether EPA-FFA gastro-resistant capsules increases IFN-γ during the studyMeasure: Increase in IFN-γ Time: 28 days
Description: To determine whether EPA-FFA gastro-resistant capsules decreases other proinflammatory chemokines and cytokines.Measure: Reduction in proinflammatory chemokines and cytokines. Time: 28 days
Description: To evaluate the safety of EPA-FFA gastro-resistant capsules in the treatment of COVID-19 (SARS-CoV-2) by assessing subjects clinical lab parameters and vital signs, and the number and proportion of subjects with AEs.Measure: Safety - Vitals, AEs and Clinical lab parameters Time: throughout the study, about 3 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports